v3.26.1
FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Changes in Level 3 Financial Instruments Measured on a Recurring Basis The following tables present the changes in the Company's Level 3 financial instruments that are measured at fair value on a recurring basis.
Accrued Contingent Consideration
Balance at September 30, 2025
$3,571 
Contingent consideration accrued at time of business combination7,600 
Change in fair value of contingent consideration included in operating expenses940 
Contingent consideration paid— 
Balance at June 30, 2026$12,111 
Accrued Contingent Consideration
Balance at September 30, 2024(1)
$2,154 
Contingent consideration accrued at time of business combination1,260 
Change in fair value of contingent consideration included in operating expenses440 
Contingent consideration paid(60)
Balance at June 30, 2025
$3,794 
__________________________
1.In connection with the sale of the Healthcare RCM Business, $198 of the Company's accrued contingent consideration (as of September 30, 2024) were classified as "Current liabilities held for sale" in the accompanying condensed consolidated balance sheets and were not included in this amount.